Key facts
- This page summarizes Gevorg Grigoryan's Form 3 filing for Generate Biomedicines, Inc. (GENB).
- 0 reported transactions and 4 derivative rows are listed below.
- Accepted by SEC: 26 Feb 2026, 20:46.
Gevorg Grigoryan - 26 Feb 2026 Form 3 Insider Report for Generate Biomedicines, Inc. (GENB)
- Reporting relationship
- Chief Technology Officer
- Issuer ticker
- GENB
- Reported as of
- 26 Feb 2026
- Net transaction value
- $0
- Reporting owner signature
- /s/ Michael Wolf, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
3 source fields
Reporting owner
1 detail
Key filing fact
Gevorg Grigoryan filed Form 3 for Generate Biomedicines, Inc. (GENB) on 26 Feb 2026.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reporting Owners (1)
CIK 0002108976
Primary reporting owner
Grigoryan Gevorg
- Relationship
- Chief Technology Officer
- Address
- GENERATE BIOMEDICINES, INC., 101 SOUTH STREET, SUITE 900, SOMERVILLE
- Signature
- /s/ Michael Wolf, Attorney-in-Fact
- Signature date
- 26 Feb 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
GENB
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 659,973
- Date
- 26 Feb 2026
- Ownership
- Direct
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
GENB
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 26 Feb 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 131,665
- Exercise price
- $6.05
- Footnotes
- F1
GENB
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 26 Feb 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 131,665
- Exercise price
- $7.19
- Footnotes
- F2
GENB
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 26 Feb 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 131,665
- Exercise price
- $7.25
- Footnotes
- F3
GENB
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 26 Feb 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 230,414
- Exercise price
- $9.15
- Footnotes
- F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
The shares underlying this option vest in sixteen equal quarterly installments following March 22, 2022, subject to the Reporting Person's continued service on each such vesting date.
Footnote F2
The shares underlying this option vest in sixteen equal quarterly installments following September 1, 2023, subject to the Reporting Person's continued service on each such vesting date.
Footnote F3
The shares underlying this option vest in sixteen equal quarterly installments following March 1, 2024, subject to the Reporting Person's continued service on each such vesting date.
Footnote F4
25% of the shares underlying this option shall vest on March 1, 2026 with the remainder vesting in twelve equal quarterly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.
SEC remarks
Exhibit 24 - Power of Attorney